Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics and expands TAM with presence in 7 of the 10 most common cancers “Bringing Decipher into the Veracyte family ...

(RTTNews) - Genomic diagnostics company Veracyte, Inc. (VCYT) and precision oncology company Decipher Biosciences, Inc. announced Wednesday that they have entered into a definitive agreement through ...

Veracyte (NASDAQ:VCYT) and Decipher Biosciences (DECI), commercial-stage precision oncology company focused on urologic cancers, inked a definitive acquisition agreement under which former will ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2021, which were in line with its previously ...

Just three months ago, Veracyte laid out $600 million to buy Decipher Biosciences and its genomic prostate cancer test. Now, that diagnostic has racked up new data showing it can help identify ...

SAN DIEGO, Feb. 18, 2020 /PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers, today announced ...

San Diego-based Decipher Biosciences, a provider of genomic testing for urological cancer, has filed for an IPO, saying it is looking to raise up to $100M in an offering on the Nasdaq Global Market.

SAN DIEGO, May 10, 2018 /PRNewswire/ -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced that it will present results from seven studies featuring its Decipher® ...

GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...

SAN DIEGO, Feb. 3, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement to provide its Decipher ® prostate cancer test to FEDMED Payors. FEDMED is ...

SINGAPORE & SAN CARLOS, Calif.--(BUSINESS WIRE)--Engine Biosciences (“Engine”) today announced the successful completion of an oversubscribed $43 million Series A funding round. Engine identifies ...